Kelley Discusses Efficacy and Safety Considerations With the STRIDE Regimen in HCC

Dr Kelley discusses standard first-line treatment options for patients with advanced HCC, key findings from the phase 3 HIMALAYA trial, and the safety profile of the STRIDE regimen in this population.

Related Keywords

Durvalumab Imfinzi ,R Katie Kelley ,Ashling Wahner ,Twitter ,Linkedin ,Department Of Medicine Hematology Oncology ,Astrazeneca ,Cancer Immunotherapy Program ,Facebook ,Single Tremelimumab Actl ,Regular Interval Durvalumab ,Apple Podcasts ,Google Podcasts ,Amazon Music ,D ,University Of California San Francisco Helen Diller Family Comprehensive Cancer Center ,